Checkpoint Therapeutics Stock Price, News & Analysis

Checkpoint Therapeutics reported its second-quarter financial results on August 12, 2022, highlighting key advancements in the clinical development of cosibelimab for cutaneous squamous cell carcinoma (cSCC). Interim results from a pivotal trial showed a confirmed objective response rate of 54.8%. They successfully held pre-BLA meetings with the FDA, paving the way for a BLA submission for both metastatic and locally advanced cSCC by late 2022. However, the company faced a net loss of $14.1 million for the quarter, with cash reserves declining to $30.9 million.

Checkpoint Therapeutics (NASDAQ: CKPT) reported positive interim results for its anti-PD-L1 antibody, cosibelimab, in patients with locally advanced cutaneous squamous cell carcinoma (cSCC).

The objective response rate (ORR) was 54.8% based on an independent review of 31 patients, exceeding the expected lower bound of 25%. The company is in discussions with the FDA for potential inclusion of this indication in its Biologics License Application (BLA) submission, planned for later this year, reflecting positive momentum in the development of cosibelimab.

Checkpoint Therapeutics announced positive results from its pivotal trial of cosibelimab, an anti-PD-L1 antibody, for treating metastatic cutaneous squamous cell carcinoma (cSCC) at the 2022 ASCO Annual Meeting. The trial included 78 patients across 24 sites and showed a confirmed objective response rate of 48.7%. Notably, 76% of these responses were ongoing at the time of analysis. The safety profile was generally favorable, with the most common adverse events being fatigue and rash. A Biologics License Application is planned for submission in Q4 2022.

Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) announced that CEO James Oliviero will present a company overview at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 3:00 p.m. ET. The management team will also engage in one-on-one meetings. A live webcast of the presentation can be accessed on Checkpoint's website for about 30 days post-event. Checkpoint focuses on novel oncology treatments, including the evaluation of cosibelimab and olafertinib for solid tumor cancers.

Checkpoint Therapeutics announces it has received waivers for pediatric clinical studies from the EMA and MHRA for cosibelimab in cutaneous squamous cell carcinoma (cSCC). This decision allows Checkpoint to expedite marketing authorization applications without the need for costly pediatric trials in Europe. Positive topline data from a recent clinical trial supports their upcoming Biologics License Application (BLA) later this year. Cosibelimab is a promising anti-PD-L1 therapy aimed at enhancing immune response against cSCC.

Checkpoint Therapeutics (CKPT) reported positive topline results from its registration-enabling study of cosibelimab for metastatic cutaneous squamous cell carcinoma (cSCC), expecting to submit a Biologics License Application (BLA) in 2022. As of March 31, 2022, the company had $41.5 million in cash, down from $54.7 million. R&D expenses rose significantly to $14.7 million from $4.2 million year-over-year, while net loss increased to $16.8 million, or $0.20 per share. The company remains focused on advancing its oncology pipeline with a disruptive pricing strategy.

Checkpoint Therapeutics (CKPT) announced that the pivotal trial results of cosibelimab for metastatic cutaneous squamous cell carcinoma (cSCC) will be presented at the 2022 ASCO Annual Meeting, scheduled for June 3-7, 2022. Following positive topline data revealed in January 2022, a Biologics License Application (BLA) submission is planned for later this year. Cosibelimab is a fully-human monoclonal antibody designed to block PD-L1, aiming to restore anti-tumor T cell responses. cSCC represents a significant health concern, with an estimated 40,000 advanced cases annually in the U.S.

Checkpoint Therapeutics (NASDAQ: CKPT) announced participation in the Fortress Biotech Virtual R&D Summit on April 5-6, 2022. Management will present a corporate overview and join a panel discussion on April 6 at 2:15 p.m. ET. The Summit highlights Fortress' diverse pipeline. Checkpoint's lead product, cosibelimab, is in a Phase 1 trial for recurrent or metastatic cancers, with plans to submit a Biologics License Application for cutaneous squamous cell carcinoma later this year. The webcast will be available on their Investor Relations page for 30 days post-event.

Checkpoint Therapeutics (CKPT) reported its financial results for the year ended December 31, 2021, highlighting a net loss of $56.7 million ($0.75 per share), up from $23.1 million ($0.41 per share) in 2020. The company increased its cash position to $54.7 million from $40.8 million a year prior. Significant developments include positive results for its anti-PD-L1 therapy, cosibelimab, in treating metastatic cutaneous squamous cell carcinoma, with a promising 47.4% objective response rate. The company plans to submit a Biologics License Application later in 2022.